Table 2.
Overview of adverse events (AEs).
| Cadonilimab 15 mg/kg Q3W | Cadonilimab 10 mg/kg Q3W | Overall | |
|---|---|---|---|
| (N = 49) | (N = 20) | (N = 69) | |
| TRAEs, n (%) | 48 (98.0) | 19 (95.0) | 67 (97.1) |
| Grade ≥3 TRAEs, n (%) | 29 (59.2) | 5 (25.0) | 34 (49.3) |
| Serious TRAEs, n (%) | 28 (57.1) | 7 (35.0) | 35 (50.7) |
| TRAEs leading to cadonilimab and anlotinib discontinuation, n (%) | 3 (6.1) | 1 (5.0) | 4 (5.8) |
| TRAEs leading to cadonilimab discontinuation, n (%) | 8 (16.3) | 1 (5.0) | 9 (13.0) |
| TRAEs leading to anlotinib discontinuation, n (%) | 7 (14.3) | 1 (5.0) | 8 (11.6) |
| TRAEs leading to death, n (%) | 1 (2.0) | 0 | 1 (1.4) |
TRAEs treatment-related adverse events, Q3W every 3 weeks.